Discovery Laboratories Inc (DSCO)

1.82
0.15 7.61
NASDAQ : Health Care
Prev Close 1.97
Open 1.90
Day Low/High 1.81 / 2.00
52 Wk Low/High 1.42 / 8.12
Volume 98.76K
Avg Volume 94.60K
Exchange NASDAQ
Shares Outstanding 8.19M
Market Cap 31.62M
EPS -7.25
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

4 Stocks Under $10 Making Big Moves Higher

4 Stocks Under $10 Making Big Moves Higher

When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.

Discovery Labs Announces Top Line Results Of AEROSURF® Phase 2a Clinical Program In Premature Infants 29 To 34 Weeks Gestational Age

Discovery Labs Announces Top Line Results Of AEROSURF® Phase 2a Clinical Program In Premature Infants 29 To 34 Weeks Gestational Age

Encouraging phase 2a data suggest that aerosolized KL4 surfactant delivered to premature infants with RDS may decrease nCPAP failure and the need for intubation

Discovery Labs To Announce Results From AEROSURF® Phase 2a Expansion Clinical Trial

Discovery Labs To Announce Results From AEROSURF® Phase 2a Expansion Clinical Trial

Conference Call Scheduled for Thursday, November 12, 2015 at 8:00 a.m. Eastern Time

Discovery Labs Announces Completion Of Enrollment In AEROSURF® Phase 2a Dose Expansion Trial

Discovery Labs Announces Completion Of Enrollment In AEROSURF® Phase 2a Dose Expansion Trial

Top-line Results Expected to be Released in Mid-November

Discovery Labs Announces Enrollment Of First Patient In AEROSURF® Phase 2a Dose Expansion Trial

Discovery Labs Announces Enrollment Of First Patient In AEROSURF® Phase 2a Dose Expansion Trial

Building on results of the recently concluded phase 2a clinical trial, this phase will assess higher and repeat doses of aerosolized KL4 surfactant

Discovery Labs Announces Results Of Phase 2a Clinical Trial Of AEROSURF®

Discovery Labs Announces Results Of Phase 2a Clinical Trial Of AEROSURF®

Encouraging safety and physiological data suggest that aerosolized KL4 surfactant can be delivered to the lung of premature infants with respiratory distress syndrome

Discovery Labs To Announce Results From AEROSURF® Phase 2a Clinical Trial

Discovery Labs To Announce Results From AEROSURF® Phase 2a Clinical Trial

Conference Call Scheduled for Thursday, May 14, 2015 at 8:00 a.m. Eastern Time

5 Stocks Ready for Breakouts: Qiwi, RadNet and More

5 Stocks Ready for Breakouts: Qiwi, RadNet and More

These stocks are poised to break out and trade higher from current levels.

Discovery Labs Announces Strategic Collaboration With Battelle For AEROSURF® Program

Discovery Labs Announces Strategic Collaboration With Battelle For AEROSURF® Program

- Companies will Co-Invest to Advance Aerosolization Technology to a Phase 3 / Commercial-Ready Device -

Your September Biotech Back-to-School Calendar

Your September Biotech Back-to-School Calendar

The biotech sector hews close to an academic calendar and September marks the start of the busy, event-filled push into the end of the year.